Amiodarone-induced thyrotoxicosis: A review

Minerva Endocrinologica

Volumn 33, Issue 3, 2008, Pages 213-228

  Piga, M ^a   Serra, A ^a   Boi, F ^a   Tanda, M L ^b   Martino, E ^c   Mariotti, S ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b UNIVERSITY OF INSUBRIA   (Italy)

^c UNIVERSITY OF PISA   (Italy)

Author keywords

Amiodarone; Thyrotoxicosis, diagnosis; Thyrotoxicosis, therapy

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR; DEXAMETHASONE; GLUCOCORTICOID; INTERLEUKIN 6; IODINE; IODINE 131; IOPANOIC ACID; LEVOTHYROXINE; LIOTHYRONINE; LITHIUM CARBONATE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PERTECHNETIC ACID TC 99M; POTASSIUM PERCHLORATE; PREDNISONE; PROPYLTHIOURACIL; RADIOACTIVE IODINE; SEX HORMONE BINDING GLOBULIN; THIAMAZOLE; THIONAMIDE; THYROGLOBULIN; THYROTROPIN; THYROXINE; THYROXINE DEIODINASE; ANTIARRHYTHMIC AGENT; DIAGNOSTIC AGENT; IL6 PROTEIN, HUMAN; PERCHLORIC ACID; POTASSIUM DERIVATIVE; UNCLASSIFIED DRUG;

APLASTIC ANEMIA; COLOR ULTRASOUND FLOWMETRY; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG WITHDRAWAL; FEVER; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART PALPITATION; HISTOCOMPATIBILITY; HUMAN; HYPOTHYROIDISM; IODINE DEFICIENCY; LIOTHYRONINE BLOOD LEVEL; LONG TERM CARE; OXYGEN CONSUMPTION; PAIN; PATHOGENESIS; PLASMAPHERESIS; REVIEW; RISK BENEFIT ANALYSIS; SKIN DISEASE; THYROGLOBULIN BLOOD LEVEL; THYROID FUNCTION; THYROID SCINTISCANNING; THYROIDECTOMY; THYROIDITIS; THYROTOXICOSIS; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TOXIC GOITER; TREATMENT DURATION; VASCULARIZATION; WEIGHT REDUCTION; BLOOD; CHEMICALLY INDUCED DISORDER; CLASSIFICATION; ECHOGRAPHY; THYROID DISEASE;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; HUMANS; INTERLEUKIN-6; IODINE; IODINE RADIOISOTOPES; IOPANOIC ACID; LITHIUM CARBONATE; PERCHLORIC ACID; PLASMAPHERESIS; POTASSIUM COMPOUNDS; TECHNETIUM TC 99M SESTAMIBI; THYROID DISEASES; THYROIDECTOMY; THYROTOXICOSIS; ULTRASONOGRAPHY, DOPPLER, COLOR;

EID: 58149377805     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Review

References (113)

1. Charlier R, Deltour G, Tondeur R, Binon F. [Studies in the benzofuran series. VII. Preliminary pharmacological study of 2-butyl-3-(3,5-diiodo-4-beta- N-diethylaminoethoxybenzoyl)-benzofuran.]. Arch Int Pharmacodyn Ther 1962;139:255-64.
2. Deltour G, Binon F, Tondeur R, Goldenberg C, Henaux F, Sion R et al. [Studies in the benzofuran series. VI. Coronary-dilating activity of alkylated and aminoalkylated derivatives of 3-benzoylbenzofuran.]. Arch Int Pharmacodyn Ther 1962;139:247-54.
3. Nivet M. [Amiodarone: new treatment of angina pectoris]. Therapeutique 1968;44:551-4.
4. Singh BN, Vaughan Williams EM. The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br J Pharmacol 1970;39:657-67.
5. Charlier R, Delaunois G, Bauthier J, Deltour G. [Research on the benzofuran series. XL. Anti-arrhythmic properties of amiodarone]. Cardiologia 1969;54:83-90.
6. Rosenbaum MB, Chiale PA, Halpern MS, Nau GJ, Przybylski J, Levi RJ et al. Clinical efficacy of amiodarone as an antiarrhythmic agent. Am J Cardiol 1976;38:934-44.
7. Latini R, Tognoni G, Kates RE. Clinical pharmacokinetics of amiodarone. Clin Pharmacokinet 1984;9:136-56.
8. Barillon A, Himbert J. [Amiodarone and the thyroid]. Presse Med 1971;79:1498.
9. Massin JP, Thomopoulos P, Karam J, Savoie JC. [The thyroid risk of a new iodized coronaro-dilator: amiodarone (cordarone)). Ann Endocrinol (Paris) 1971;32:438-48.
10. Martino E, Bartalena L, Bogazzi F, Braverman LE. The effects of amiodarone on the thyroid. Endocr Rev 2001;22:240-54.
11. Meurisse M, Gollogly L, Degauque C, Fumal I, Defechereux T, Hamoir E. Iatrogenic thyrotoxicosis: causal circumstances, pathophysiology, and principles of treatment-review of the literature. World J Surg 2000;24:1377-85.
12. Labouche F, Masse R, Jan A, Grullier A, Herry B, Bailleux A. [Cutaneous pigmentation during treatments with amiodarone chlorhydrate]. Bull Soc Fr Dermatol Syphiligr 1971;78:27-30.
13. Wanet J, Achten G, Barchewitz G, Mestdagh C, Vastesaeger M. [Amiodarone and cutaneous depostis. Clinical and histological study]. Ann Dermatol Syphiligr (Paris) 1971;98:131-40.
14. Watillon M, Lavergne G, Weekers JF. [Corneal lesions during treatment with cordarone (amiodarone hydrochloride)]. Bull Soc Belge Ophtalmol 1968;150:715-26.
15. Peyresblanques J. [Keratopathy due to cordarone (cornelal thesaurismosis due to amiodarone)]. Bull Soc Ophtalmol Fr 1969;69:973-7.
16. Miller HA. [Keratopathy following treatment with cordarone (amiodarone hydrochloride)]. Bull Soc Ophtalmol Fr 1969;69:1059-65.
17. Bakker O, van Beeren HC, Wiersinga WM. Desethylamiodarone is a noncompetitive inhibitor of the binding of thyroid hormone to the thyroid hormone beta 1-receptor protein. Endocrinology 1994;134:1665-70.
18. Rao RH, McCready VR, Spathis GS. Iodine kinetic studies during amiodarone treatment. J Clin Endocrinol Metab 1986;62:563-8.
19. Chiovato L, Martino E, Tonacchera M, Santini F, Lapi P, Mammoli C et al. Studies on the in vitro cytotoxic effect of amiodarone. Endocrinology 1994;134:2277-82.
20. Beddows SA, Page SR, Taylor AH, McNerney R, Whitley GS, Johnstone AP et al. Cytotoxic effects of amiodarone and desethylamiodarone on human thyrocytes. Biochem Pharmacol 1989;38:4397-403.
21. Vitale M, Di Matola T, D'Ascoli F, Salzano S, Bogazzi F, Fenzi G et al. Iodide excess induces apoptosis in thyroid cells through a p53-independent mechanism involving oxidative stress. Endocrinology 2000;141:598-605.
22. Martino E, Safran M, Aghini-Lombardi F, Rajatanavin R, Lenziardi M, Fay M et al. Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Ann Intern Med 1984;101:28-34. (Pubitemid 14088063)
23. Guinet P, Pousset G, Briere J, Bianchi GG. [Iodine myxedema during amiodarone treatment]. Lyon Med 1971;226:167-71.
24. Jonckheer MH, Blockx P, Kaivers R, Wyffels G. Hyperthyroidism as a possible complication of the treatment of ischemic heart disease with amiodarone. Acta Cardiol 1973;28:192-200.
25. Keidar S, Grenadier E, Palant A. Amiodarone-induced thyrotoxicosis: four cases and a review of the literature. Postgrad Med J 1980;56:356-8.
26. Brami JL, Schlaeffer F, Sobel R. Amiodarone-induced dysthyroidism. Isr J Med Sci 1985;21:610-2.
27. Erdo an M, Güleç S, Tutar E, Guidal M, Baflkal N, Erdo an G. HLA-B40-, HLA-Cw3-, and HLA-DR5-associated susceptibility to amiodarone-induced thyroid dysfunction. Thyroid 2000;10:369-70.
28. Martino E, Aghini-Lombardi F, Mariotti S, Bartalena L, Braverman L, Pinchera A. Amiodarone: a common source of iodine-induced thyrotoxicosis. Horm Res 1987;26:158-71. (Pubitemid 17071710)
29. Brennan MD, van Heerden JA, Carney JA. Amiodarone-associated thyrotoxicosis (AAT): experience with surgical management. Surgery 1987;102:1062-7.
30. Newnham HH, Topliss DJ, Le Grand BA, Chosich N, Harper RW, Stockigt JR. Amiodarone-induced hyperthyroidism: assessment of the predictive value of biochemical testing and response to combined therapy using propylthiouracil and potassium Perchlorate. Aust N Z J Med 1988;18:37-44.
31. Fradkin JE, Wolff J. Iodide-induced thyrotoxicosis. Medicine (Baltimore) 1983;62:1-20.
32. Martino E, Aghini-Lombardi F, Lippi F, Baschieri L, Safran M, Braverman LE et al. Twenty-four hour radioactive iodine uptake in 35 patients with amiodarone associated thyrotoxicosis. J Nucl Med 1985;26:1402-7.
33. Martino E, Bartalena L, Mariotti S, Aghini-Lombardi F, Ceccarelli C, Lippi F et al. Radioactive iodine thyroid uptake in patients with amiodarone-iodine-induced thyroid dysfunction. Acta Endocrinol (Copenh) 1988;119:167-73.
34. Bartalena L, Grasso L, Brogioni S, Aghini-Lombardi F, Braverman LE, Martino E. Serum interleukin-6 in amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab 1994;78:423-7.
35. Bartalena L, Brogioni S, Grasso L, Rago T, Vitti P, Pinchera A et al. Interleukin-6: a marker of thyroid-destructive processes? J Clin Endocrinol Metab 1994;79:1424-7.
36. Roti E, Minelli R, Gardini E, Bianconi L, Braverman LE. Thyrotoxicosis followed by hypothyroidism in patients treated with amiodarone. A possible consequence of a destructive process in the thyroid. Arch Intern Med 1993;153:886-92.
37. Roti E, Minelli R, Gardini E, Bianconi L, Gavaruzzi G, Ugolotti G et al. Iodine-induced subclinical hypothyroidism in euthyroid subjects with a previous episode of amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab 1992;75:1273-7.
38. Zonenberg A, Telejko B, Szelachowska M, Modzelewska A, Nikolajuk A, Gorska M. [Markers of endothelial dysfunction in patients with iodine induced hyperthyroidism]. Endokrynol Pol 2006;57:210-7.
39. Brennan MD, Erickson DZ, Carney JA, Bahn RS. Nongoitrous (type I) amiodarone-associated thyrotoxicosis: evidence of follicular disruption in vitro and in vivo. Thyroid 1995;5:177-83.
40. Smyrk TC, Goellner JR, Brennan MD, Carney JA. Pathology of the thyroid in amiodarone-associated thyrotoxicosis. Am J Surg Pathol 1987;11:197-204.
41. Bogazzi F, Raggi F, Ultimieri F, Russo D, Cosci C, Cecchetti P et al. Uptake of amiodarone by thyroidal and non-thyroidal cell lines. J Endocrinol Invest 2006;29:61-6. (Pubitemid 43355837)
42. Rose NR, Rasooly L, Saboori AM, Burek CL. Linking iodine with autoimmune thyroiditis. Environ Health Perspect 1999;107:749-52.
43. Ruwhof C, Drexhage HA. Iodine and thyroid autoimmune disease in animal models. Thyroid 2001;11:427-36. (Pubitemid 32494592)
44. Martino E, Aghini-Lombardi F, Bartalena L, Grasso L, Loviselli A, Velluzzi F et al. Enhanced susceptibility to amiodarone-induced hypothyroidism in patients with thyroid autoimmune disease. Arch Intern Med 1994;154:2722-6.
45. Safran M, Martino E, Aghini-Lombardi F, Bartalena L, Balzano S, Pinchera A et al. Effect of amiodarone on circulating antithyroid antibodies. Bmj 1988;297:456-7.
46. Weetman AP, Bhandal SK, Burrin JM, Robinson K, McKenna W. Amiodarone and thyroid autoimmunity in the United Kingdom. BMJ 1988;297:33.
47. Loviselli A, Bartalena L, Balzano S, Aghini-Lombardi F, Sica V, Pilosu R et al. Absence of serum thyroid hormone autoantibodies in patients chronically treated with amiodarone. J Endocrinol Invest 1988;11:323-5.
48. Bogazzi F, Bartalena L, Dell'Unto E, Tomisti L, Rossi G, Pepe P et al. Proportion of type 1 and type 2 amiodarone-induced thyrotoxicosis has changed over a 27-year period in Italy. Clin Endocrinol (Oxf) 2007;67:533-7.
49. Sato K, Miyakawa M, Eto M, Inaba T, Matsuda N, Shiga T et al. Clinical characteristics of amiodarone-induced thyrotoxicosis and hypothyroidism in Japan. Endocr J 1999;46:443-51.
50. Mariotti S, Loviselli A, Murenu S, Sau F, Valentino L, Mandas A et al. High prevalence of thyroid dysfunction in adult patients with beta-thalassemia major submitted to amiodarone treatment. J Endocrinol Invest 1999;22:55-63.
51. Trip MD, Wiersinga W, Plomp TA. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med 1991;91:507-11.
52. Stäubli M, Studer H. Amiodarone-treated patients with suppressed TSH test are at risk of thyrotoxicosis. Klin Wochenschr 1985;63:168-75.
53. Miaskiewicz SL, Amico JA, Follansbee WP, Levey GS. Amiodarone-associated thyrotoxicosis masquerading as painful thyroiditis. Ann Intern Med 1987;107:118-9.
54. Balzano S, Sau F, Bartalena L, Ruscazio M, Balestrieri A, Cherchi A et al. Diagnosis of amiodarone-iodine-induced thyrotoxicosis(AIIT) associated with severe nonthyroidal illness. J Endocrinol Invest 1987;10:589-91. (Pubitemid 18058116)
55. Ralls PW, Mayekawa DS, Lee KP, Colletti PM, Radin DR, Boswell WD et al. Color-flow Doppler sonography in Graves disease: "thyroid inferno". AJR Am J Roentgenol 1988;150:781-4.
56. Ota H, Amino N, Morita S, Kobayashi K, Kubota S, Fukata S et al. Quantitative measurement of thyroid blood flow for differentiation of painless thyroiditis from Graves' disease. Clin Endocrinol (Oxf) 2007;67:41-5.
57. Boi F, Loy M, Piga M, Serra A, Atzeni F, Mariotti S. The usefulness of conventional and echo colour Doppler sonography in the differential diagnosis of toxic multinodular goitres. Eur J Endocrinol 2000;143:339-46.
58. Hiromatsu Y, Ishibashi M, Miyake I, Soyejima E, Yamashita K, Koike N et al. Color Doppler ultrasonography in patients with subacute thyroiditis. Thyroid 1999;9:1189-93.
59. Vitti P, Rago T, Mazzeo S, Brogioni S, Lampis M, De Liperi A et al. Thyroid blood flow evaluation by colorflow Doppler sonography distinguishes Graves' disease from Hashimoto's thyroiditis. J Endocrinol Invest 1995;18:857-61. (Pubitemid 26064023)
60. Bogazzi F, Bartalena L, Brogioni S, Mazzeo S, Vitti P, Burelli et al. Color flow Doppler sonography rapidly differentiates type I and type II amiodarone-induced thyrotoxicosis. Thyroid 1997;7:541-5. (Pubitemid 27371790)
61. Bogazzi F, Martino E, Dell'Unto E, Brogioni S, Cosci C, Aghini-Lombardi F et al. Thyroid color flow doppler sonography and radioiodine uptake in 55 consecutive patients with amiodarone-induced thyrotoxicosis. J Endocrinol Invest 2003;26:635-40. (Pubitemid 37270694)
62. Eaton SE, Euinton HA, Newman CM, Weetman AP, Bennet WM. Clinical experience of amiodarone-induced thyrotoxicosis over a 3-year period: role of colour-flow Doppler sonography. Clin Endocrinol (Oxf) 2002;56:33-8.
63. Macedo TA, Chammas MC, Jorge PT, Souza LP, Farage L, Watanabe T et al. Differentiation between the two types of amiodarone-associated thyrotoxicosis using duplex and amplitude Doppler sonography. Acta Radiol 2007;48:412-21.
64. Wong R, Cheung W, Stockigt JR, Topliss DJ. Heterogeneity of amiodarone-induced thyrotoxicosis: evaluation of colour-flow Doppler sonography in predicting therapeutic response. Intern Med J 2003;33:420-6.
65. Loy M, Perra E, Melis A, Cianchetti ME, Piga M, Serra A et al. Color-flow Doppler sonography in the differential diagnosis and management of amiodarone-induced thyrotoxicosis. Acta Radiol 2007;48:628-34.
66. Brian SR, Cheng DW, Goldberg PA. Unusual case of amiodarone-induced thyrotoxicosis: "illicit" use of a technetium scan to diagnose a transiently toxic thyroid nodule. Endocr Pract 2007;13:413-6.
67. Bartalena L, Brogioni S, Grasso L, Martino E. Increased serum interleukin-6 concentration in patients with subacute thyroiditis: relationship with concomitant changes in serum T4-binding globulin concentration. J Endocrinol Invest 1993;16:213-8. (Pubitemid 23137961)
68. Chiu ML, Kronauge JF, Piwnica-Worms D. Effect of mitochondrial and plasma membrane potentials on accumulation of hexakis (2-methoxyisobutylisonitrile) technetium(I) in cultured mouse fibroblasts. J Nucl Med 1990;31:1646-53. (Pubitemid 20347047)
69. Delmon-Moingeon LI, Piwnica-Worms D, Van den Abbeele AD, Holman BL, Davison A, Jones AG. Uptake of the cation hexakis(2-methoxyisobutylisonitrile)- technetium-99m by human carcinoma cell lines in vitro. Cancer Res 1990;50:2198-202.
70. Piwnica-Worms D, Holman BL. Noncardiac applications of hexakis(alkylisonitrile) technetium-99m complexes. J Nucl Med 1990;31:1166-7.
71. O'Doherty MJ, Kettle AG, Wells P, Collins RE, Coakley AJ. Parathyroid imaging with technetium-99m-sestamibi: preoperative localization and tissue uptake studies. J Nucl Med 1992;33:313-8.
72. Sandrock D, Merino M, Norton J. Light- and electron-microscopic analyses of parathyroid tumours explain results of Tl-201/Tc-99m parathyroid scintigraphy [Abstract]. Eur J Nucl Med 1989;15:410.
73. Boi F, Lai ML, Deias C, Piga M, Serra A, Uccheddu A et al. The usefulness of 99mTc-SestaMIBI scan in the diagnostic evaluation of thyroid nodules with oncocytic cytology. Eur J Endocrinol 2003;149:493-8.
74. Kao CH, Lin WY, Wang SJ, Yeh SH. Visualization of suppressed thyroid tissue by Tc-99m MIBI. Clin Nucl Med 1991;16:812-4.
75. Kao CH, Wang SJ, Liao SQ, Lin WY, Hsu CY. Quick diagnosis of hyperthyroidism with semiquantitative 30-minute technetium-99m-methoxy-isobutyl- isonitrile thyroid uptake. J Nucl Med 1993;34:71-4.
76. 99mTc-tetrofosmin. Ann Nucl Med 2004;18:79-95.
77. Johannessen J. Endocrine organs, part two: the thyroid gland. In Electron microscopy un human medicine. New York: McGraw-Hill; 1981. p. 27-107.
78. Kroemer G, Dallaporta B, Resche-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis. Annu Rev Physiol 1998;60:619-42.
79. 99mTc-MIBI be used to visualize the apoptotic MCF7 human breast cancer cells? Cell Mol Biol (Noisy-le-grand) 2001;47:467-71.
80. 99mTc-sestaMIBI thyroid scan in the differential diagnosis and management of Amiodarone-induced thyrotoxicosis. Eur J Endocrinol 2008 [Epub ahead of print].
81. Wolff J. Perchlorate and the thyroid gland. Pharmacol Rev 1998;50:89-105.
82. Martino E, Aghini-Lombardi F, Mariotti S, Lenziardi M, Baschieri L, Braverman LE et al. Treatment of amiodarone associated thyrotoxicosis by simultaneous administration of potassium perchlorate and methimazole. J Endocrinol Invest 1986;9:201-7. (Pubitemid 16072801)
83. Reichert LJ, de Rooy HA: Treatment of amiodarone induced hyperthyroidism with potassium perchlorate and methimazole during amiodarone treatment. BMJ 1989;298:1547-8.
84. Trotter WR. The relative toxicity of antithyroid drugs. J New Drugs 1962;2:333-43.
85. Wenzel KW, Lente JR. Similar effects of thionamide drugs and perchlorate on thyroid-stimulating immunoglobulins in Graves' disease: evidence against an immunosuppressive action of thionamide drugs. J Clin Endocrinol Metab 1984;58:62-9.
86. Basaria S, Cooper DS. Amiodarone and the thyroid. Am J Med 2005;118:706-14.
87. Lazarus JH. The effects of lithium therapy on thyroid and thyrotropin-releasing hormone. Thyroid 1998;8:909-13.
88. Dickstein G, Shechner C, Adawi F, Kaplan J, Baron E, Ish-Shalom S. Lithium treatment in amiodarone-induced thyrotoxicosis. Am J Med 1997;102:454-8.
89. Wu SY, Chopra IJ, Solomon DH, Bennett LR. Changes in circulating iodothyronines in euthyroid and hyperthyroid subjects given ipodate (Oragrafin), an agent for oral cholecystography. J Clin Endocrinol Metab 1978;46:691-7.
90. Martino E, Balzano S, Bartalena L, Loviselli A, Sica V, Petrini L et al. Therapy of Graves' disease with sodium ipodate is associated with a high recurrence rate of hyperthyroidism. J Endocrinol Invest 1991;14:847-51.
91. Bogazzi F, Miccoli P, Berti P, Cosci C, Brogioni S, Aghini-Lombardi F et al. Preparation with iopanoic acid rapidly controls thyrotoxicosis in patients with amiodarone-induced thyrotoxicosis before thyroidectomy. Surgery 2002;132:1114-7; discussion 1118.
92. Bogazzi F, Bartalena L, Cosci C, Brogioni S, Dell'Unto E, Grasso L et al. Treatment of type II amiodarone-induced thyrotoxicosis by either iopanoic acid or glucocorticoids: a prospective, randomized study. J Clin Endocrinol Metab 2003;88:1999-2002.
93. Uzzan B, Pussard E, Leon A, Bekhechi D, Krivitzky A, Modigiani E et al. The effects of plasmapheresis on thyroid hormone and plasma drug concentrations in amiodarone-induced thyrotoxicosis. Br J Clin Pharrnacol 1991;31:371-2.
94. Aghini-Lombardi F, Mariotti S, Fosella PV, Grasso L, Pinchera A, Braverman LE et al. Treatment of amiodarone iodine-induced thyrotoxicosis with plasmapheresis and methimazole. J Endocrinol Invest 1993;16:823-6. (Pubitemid 24026798)
95. Diamond TH, Rajagopal R, Ganda K, Manoharan A, Luk A. Plasmapheresis as a potential treatment option for amiodarone-induced thyrotoxicosis. Intern Med J 2004;34:369-70; author reply 370-1.
96. Harjai KJ, Licata AA. Effects of amiodarone on thyroid function. Ann Intern Med 1997;126:63-73.
97. Bartalena L, Brogioni S, Grasso L, Bogazzi F, Burelli A, Martino E. Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study. J Clin Endocrinol Metab 1996;81:2930-3.
98. Wimpfheimer C, Staubli M, Schadelin J, Studer H. Prednisone in amiodarone-induced thyrotoxicosis. Br Med J (Clin Res Ed) 1982;284:1835-6.
99. Dietlein M, Schicha H. Amiodarone-induced thyrotoxicosis due to destructive thyroiditis: therapeutic recommendations. Exp Clin Endocrinol Diabetes 2005;113: 145-51.
100. Franklyn JA, Gammage MD. Treatment of amiodarone-associated thyrotoxicosis. Nat Clin Pract Endocrinol Metab 2007;3:662-6.
101. Bogazzi F, Bartalena L, Tomisti L, Rossi G, Tanda ML, Dell'Unto E et al. Glucocorticoid response in amiodarone-induced thyrotoxicosis resulting from destructive thyroiditis is predicted by thyroid volume and serum free thyroid hormone concentrations. J Clin Endocrinol Metab 2007;92:556-62.
102. Newman CM, Price A, Davies DW, Gray TA, Weetman AP. Amiodarone and the thyroid: a practical guide to the management of thyroid dysfunction induced by amiodarone therapy. Heart 1998;79:121-7. (Pubitemid 28157329)
103. Davies PH, Franklyn JA, Sheppard MC. Treatment of amiodarone induced thyrotoxicosis with Carbimazole alone and continuation of amiodarone. Bmj 1992;305:224-5.
104. Trip MD, Duren DR, Wiersinga WM. Two cases of amiodarone-induced thyrotoxicosis successfully treated with a short course of antithyroid drugs while amiodarone was continued. Br Heart J 1994;72:266-8.
105. Hermida JS, Tcheng E, Jarry G, Moullart V, Arlot S, Rey JL et al. Radioiodine ablation of the thyroid to prevent recurrence of amiodarone-induced thyrotoxicosis in patients with resistant tachyarrhythmias. Europace 2004;6:169-74.
106. Hermida JS, Jarry G, Tcheng E, Moullart V, Arlot S, Rey JL et al. Radioiodine ablation of the thyroid to allow the reintroduction of amiodarone treatment in patients with a prior history of amiodarone-induced thyrotoxicosis. Am J Med 2004;116:345-8.
107. Farwell AP, Abend SL, Huang SK, Patwardhan NA, Braverman LE. Thyroidectomy for amiodarone-induced thyrotoxicosis. Jama 1990;263:1526-8.
108. Franzese CB, Fan CY, Stack BC, Jr. Surgical management of amiodarone-induced thyrotoxicosis. Otolaryngol Head Neck Surg 2003;129:565-70.
109. Batori M, Nardi M, Chatelou E, Straniero A, Makrypodi M, Ruggieri M. Total thyroidectomy in amiodarone-induced thyrotoxicosis. Preoperative, intraoperative and postoperative considerations. Eur Rev Med Pharmacol Sci 2006;10:187-90.
110. Meurisse M, Hamoir E, D'Silva M, Joris J, Hennen G. Amiodarone-induced thyrotoxicosis: is there a place for surgery? World J Surg 1993;17:622-6; discussion 627.
111. Hamoir E, Meurisse M, Defechereux T, Joris J, Vivario J, Hennen G. Surgical management of amiodarone-associated thyrotoxicosis: too risky or too effective? World J Surg 1998;22:537-42; discussion 542-533.
112. Gough J, Gough IR. Total thyroidectomy for amiodarone-associated thyrotoxicosis in patients with severe cardiac disease. World J Surg 2006;30:1957-61.
113. Berti P, Materazzi G, Bogazzi F, Ambrosini CE, Martino E, Miccoli P. Combination of minimally invasive thyroid surgery and local anesthesia associated to iopanoic acid for patients with amiodarone-induced thyrotoxicosis and severe cardiac disorders: a pilot study. Langenbecks Arch Surg 2007;392:709-13.